WO2025180385 - ANTI-EGFR/CD70 ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/180385
Publication Date
04.09.2025
International Application No.
PCT/CN2025/079201
International Filing Date
26.02.2025
Title **
[English]
ANTI-EGFR/CD70 ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-EGFR/CD70 ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
YANG, Yongfei
SUN, Xiaoxia
MAO, Ting
AN, Gao
Priority Data
PCT/CN2024/078785
27.02.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3621 | |
| EPO | Filing, Examination, Granting | 52779 | |
| Japan | Filing, Examination, Granting | 3793 | |
| South Korea | Filing, Examination, Granting | 5509 | |
| USA | Filing, Examination, Granting | 24340 |
Total:
90,042
Contact Us
Abstract[English]
Provided herein are anti-EGFR antibodies or antigen binding fragments of anti-EGFR antibodies, anti-CD70 antibodies or antigen binding fragments of anti-CD70 antibodies, and antigen-binding protein constructs (e.g., bispecific antibodies or antigen-binding fragments thereof) that specifically bind to two different antigens, such as EGFR and CD70. Additionally, the related antibody drug conjugates are also provided.[French]
L'invention concerne des anticorps anti-EGFR ou des fragments de liaison à l'antigène d'anticorps anti-EGFR, des anticorps anti-CD70 ou des fragments de liaison à l'antigène d'anticorps anti-CD70, et des constructions de protéine de liaison à l'antigène (par exemple, des anticorps bispécifiques ou des fragments de liaison à l'antigène de ceux-ci) qui se lient de manière spécifique à deux antigènes différents, tels que EGFR et CD70. De plus, l'invention concerne également des conjugués anticorps-médicament associés.